Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment
Tim Raine, Stefanos Bonovas, Johan Burisch, et al.
Journal of Crohn s and Colitis (2021) Vol. 16, Iss. 1, pp. 2-17
Closed Access | Times Cited: 608

Showing 26-50 of 608 citing articles:

Behavioral abnormalities in C57BL/6 mice with chronic ulcerative colitis induced by DSS
Yuxin Zhou, Gang Ji, Xiaoyi Yang, et al.
BMC Gastroenterology (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 21
Probiotics for the treatment of ulcerative colitis: a review of experimental research from 2018 to 2022
Cuilan Huang, Wujuan Hao, Xuyang Wang, et al.
Frontiers in Microbiology (2023) Vol. 14
Open Access | Times Cited: 21
Gut-associated lymphoid tissue attrition associates with response to anti-α4β7 therapy in ulcerative colitis
Pablo Canales-Herrerías, Mathieu Uzzan, Akihiro Seki, et al.
Science Immunology (2024) Vol. 9, Iss. 94
Open Access | Times Cited: 13
The JAK-STAT Pathway as a Therapeutic Strategy in Cancer Patients with Immune Checkpoint Inhibitor-Induced Colitis: A Narrative Review
Antonietta Gerarda Gravina, Raffaele Pellegrino, Alfonso Esposito, et al.
Cancers (2024) Vol. 16, Iss. 3, pp. 611-611
Open Access | Times Cited: 11
Metabolic Nanoregulator Remodels Gut Microenvironment for Treatment of Inflammatory Bowel Disease
Ting Xu, Xiaogang Ning, Jiayan Wu, et al.
ACS Nano (2024) Vol. 18, Iss. 9, pp. 7123-7135
Closed Access | Times Cited: 11
Diagnosis and management of inflammatory bowel disease
Lili Li, Rui Cheng, Yushan Wu, et al.
Journal of Evidence-Based Medicine (2024) Vol. 17, Iss. 2, pp. 409-433
Closed Access | Times Cited: 11
Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY)
Stephen B. Hanauer, Bruce E. Sands, Stefan Schreiber, et al.
Gastroenterology (2024) Vol. 167, Iss. 5, pp. 919-933
Open Access | Times Cited: 10
Model-informed precision dosing: State of the art and future perspectives
Iris K. Minichmayr, Erwin Dreesen, Marco Centanni, et al.
Advanced Drug Delivery Reviews (2024) Vol. 215, pp. 115421-115421
Open Access | Times Cited: 10
Inflammatory Bowel Diseases and Non-Alcoholic Fatty Liver Disease: Piecing a Complex Puzzle Together
Rossella Maresca, Irene Mignini, Simone Varca, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3278-3278
Open Access | Times Cited: 9
Challenges in IBD Research 2024: Precision Medicine
Sana Syed, Brigid S. Boland, Lauren T Bourke, et al.
Inflammatory Bowel Diseases (2024) Vol. 30, Iss. Supplement_2, pp. S39-S54
Open Access | Times Cited: 9
Harms with placebo in trials of biological therapies and small molecules as maintenance therapy in inflammatory bowel disease: a systematic review and meta-analysis
Beatriz Gros, Jonathan Blackwell, Jonathan Segal, et al.
˜The œLancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 11, pp. 1030-1040
Open Access | Times Cited: 8
Tofacitinib use in ulcerative colitis: An expert consensus for day-to-day clinical practice
Rupa Banerjee, Vishal Sharma, Rajendra Patel, et al.
Indian Journal of Gastroenterology (2024) Vol. 43, Iss. 1, pp. 22-35
Closed Access | Times Cited: 7
Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials
Marthe Kirkesæther Brun, Johanna Elin Gehin, K. H. Bjørlykke, et al.
The Lancet Rheumatology (2024) Vol. 6, Iss. 4, pp. e226-e236
Closed Access | Times Cited: 7
Ustekinumab treatment in ulcerative colitis: Real‐world data from the Swedish inflammatory bowel disease quality register
Joel Thunberg, Olle Björkqvist, Charlotte Hedin, et al.
United European Gastroenterology Journal (2022) Vol. 10, Iss. 7, pp. 631-639
Open Access | Times Cited: 35
Ozanimod: A Review in Ulcerative Colitis
Julia Paik
Drugs (2022) Vol. 82, Iss. 12, pp. 1303-1313
Open Access | Times Cited: 35
Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology
Fabio Salvatore Macaluso, Ambrogio Orlando, Claudio Papi, et al.
Digestive and Liver Disease (2022) Vol. 54, Iss. 4, pp. 440-451
Open Access | Times Cited: 33
Colorectal Cancer in Inflammatory Bowel Diseases: Epidemiology and Prevention: A Review
Elisa Marabotto, Stefano Kayali, Silvia Buccilli, et al.
Cancers (2022) Vol. 14, Iss. 17, pp. 4254-4254
Open Access | Times Cited: 32
A review of the therapeutic management of ulcerative colitis
Nasar Aslam, Sheng Wei Lo, Rafid Sikafi, et al.
Therapeutic Advances in Gastroenterology (2022) Vol. 15
Open Access | Times Cited: 31
Sphingosine 1-Phosphate Modulation in Inflammatory Bowel Diseases: Keeping Lymphocytes Out of the Intestine
Arianna Dal Buono, Roberto Gabbiadini, Ludovico Alfarone, et al.
Biomedicines (2022) Vol. 10, Iss. 7, pp. 1735-1735
Open Access | Times Cited: 30
Positioning biologics in the treatment of IBD: A practical guide – Which mechanism of action for whom?
Pascal Juillerat, Maude Martinho Grueber, Roseline Ruetsch, et al.
Current Research in Pharmacology and Drug Discovery (2022) Vol. 3, pp. 100104-100104
Open Access | Times Cited: 27
Surface-anchored microbial enzyme-responsive solid lipid nanoparticles enabling colonic budesonide release for ulcerative colitis treatment
Yipeng Zhang, Liying Wang, Zi-Dan Wang, et al.
Journal of Nanobiotechnology (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 18
Temperature-triggered in situ forming lipid mesophase gel for local treatment of ulcerative colitis
Marianna Carone, Marianne R. Spalinger, Robert A. Gaultney, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 18
Tofacitinib Versus Oral Prednisolone for Induction of Remission in Moderately Active Ulcerative Colitis [ORCHID]: A Prospective, Open-Label, Randomized, Pilot Study
Arshdeep Singh, Vandana Midha, Kirandeep Kaur, et al.
Journal of Crohn s and Colitis (2023) Vol. 18, Iss. 2, pp. 300-307
Closed Access | Times Cited: 18
Pharmacological Therapy in Inflammatory Bowel Diseases: A Narrative Review of the Past 90 Years
Marcello Imbrizi, Fernando Magro, Cláudio Saddy Rodrigues Coy
Pharmaceuticals (2023) Vol. 16, Iss. 9, pp. 1272-1272
Open Access | Times Cited: 18
Disease Clearance as a New Outcome in Ulcerative Colitis: a Systematic Review and Expert Consensus
Ferdinando D’Amico, Fernando Magro, Britta Siegmund, et al.
Inflammatory Bowel Diseases (2023) Vol. 30, Iss. 6, pp. 1009-1017
Closed Access | Times Cited: 16

Scroll to top